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“One Size Fits All”
The Strategy Begins With a Discussion*Neil J. Stone, MDI n this issue of the Journal, Navar-Boggan et al. (1)address the strategy for low-risk primary preven-tion of atherosclerotic cardiovascular disease
(ASCVD). This is a thoughtful exploration of the
impact of varying the 10-year risk thresholds pro-
posed by the cholesterol guidelines (2) to direct statin
assignments in low-risk primary prevention. The
authors use data from the Framingham Offspring
Study with the acknowledged limitation that it is
neither a geographically nor a racially diverse
sample. This acknowledgment is important: one of
the major advances in risk estimation of the new
pooled cohort equations is having a separate risk
equation for African-American subjects.SEE PAGE 1633Nonetheless, the authors (1) propose that adjusting
a ﬁxed 7.5% threshold for statin assignment in both
younger and older eligible subjects could improve
the accuracy of such assignments in reducing ASCVD
risk. They state “one size doesn’t ﬁt all.” Clinicians
should take note: the strategy used by the current
prevention guidelines agrees.
What are the characteristics of a good strategy? In a
recent book, Rumelt (3) emphasized that a good
strategy has a 3-part “kernel.” For those practicing
medicine, it begins with a diagnosis that deﬁnes or
explains the nature of the strategic challenge. There
is then a guiding policy and, lastly, a group of
coherent actions. As Rumelt noted, “The core of*Editorials published in the Journal of the American College of Cardiology
reﬂect the, views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Feinberg School of Medicine, Northwestern University,
Chicago, Illinois. Dr. Stone has reported that he has no relationships
relevant to the contents of this paper to disclose.strategy work is always the same: discovering the
critical factors in a situation and designing a way of
coordinating and focusing actions to deal with those
factors.”
The current American College of Cardiology/
American Heart Association prevention guidelines
addressed a strategic challenge: how to reduce the
burden of ASCVD in the United States. The guiding
policy for all 4 recent guidelines (lifestyle, obesity,
risk assessment, and cholesterol), which were writ-
ten, presented, and published together, was to create
clinical recommendations that ﬂowed directly from
detailed evidence reviews based on each panel’s
critical questions and to use only quality-rated
randomized clinical trials (RCTs) and meta-analyses
of RCTs (2,4–6). Each document emphasized coun-
seling on a healthy lifestyle.
One guideline focused on 3 critical questions
related to lipid-lowering therapy. Statins emerged as
having the strongest evidence for net beneﬁt in high-
risk groups. Follow-up lipid testing was recom-
mended, not only to determine the adequacy of the
statin effect but also to assess adherence to an optimal
lifestyle and the appropriate intensity of statin ther-
apy. A strategic decision was needed, however, for
lower risk primary prevention. The threshold for
statin treatment of $7.5% 10-year ASCVD risk did not
indicate automatic statin assignment. The guidelines
found evidence to support such a decision, but
mindful of the need to individualize therapy, they
provide coherent actions to accomplish this.
Although there was evidence for net beneﬁt down
to 5% risk based on 3 RCTs with exclusively primary
prevention subjects, the guideline panels recom-
mended a 7.5% guidepost, allowing the individual to
still derive beneﬁt in case overestimation occurred.
Importantly, however, the guidelines recommended
a clinician–patient risk discussion preceding the
FIGURE 1 Initiating Statin Therapy in Primary Prevention
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To reduce atherosclerotic cardiovascular disease (ASCVD) risk in adults, the 2013 blood cholesterol guidelines include statin initiation rec-
ommendations that consider differences in characteristics among individual patients. *Percent reduction in LDL-C can be used as an indication
of response and adherence to therapy, but is not in itself a treatment goal. †The Pooled Cohort Equations can be used to estimate 10-year
ASCVD risk in individuals with and without diabetes. The estimator within this application should be used to inform decision making in primary
prevention patients not on a statin. ‡Consider moderate-intensity statin as more appropriate in low-risk individuals. §For those in whom a risk
assessment is uncertain, consider factors such as primary LDL-C $160 mg/dl or other evidence of genetic hyperlipidemias, family history of
premature ASCVD with onset <55 years of age in a ﬁrst-degree male relative or <65 years of age in a ﬁrst-degree female relative, hs-CRP $2
mg/l, CAC score $300 Agatston units, or $75th percentile for age, sex, and ethnicity, ABI <0.9, or lifetime risk of ASCVD. Additional factors
that may aid in individual risk assessment may be identiﬁed in the future. kPotential ASCVD risk-reduction beneﬁts. The absolute reduction in
ASCVD events from moderate- or high-intensity statin therapy can be approximated by multiplying the estimated 10-year ASCVD risk by the
anticipated relative-risk reduction from the intensity of statin initiated (w30% for moderate-intensity statin orw45% for high-intensity statin
therapy). The net ASCVD risk-reduction beneﬁt is estimated from the number of potential ASCVD events prevented with a statin, compared to
the number of potential excess adverse effects. ¶Potential adverse effects. The excess risk of diabetes is the main consideration inw0.1 excess
cases per 100 individuals treated with a moderate-intensity statin for 1 year and w0.3 excess cases per 100 individuals treated with a high-
intensity statin for 1 year. In RCTs, both statin-treated and placebo-treated participants experienced the same rate of muscle symptoms.
The actual rate of statin-related muscle symptoms in the clinical population is unclear. Muscle symptoms attributed to statin therapy should
be evaluated. ABI ¼ ankle-brachial index; CAC ¼ coronary artery calcium; DM ¼ diabetes mellitus; hs-CRP ¼ high-sensitivity C-reactive
protein; LDL-C ¼ low-density lipoprotein cholesterol; MI ¼ myocardial infarction; RCT ¼ randomized controlled trial. Adapted with permission
from Stone et al. (2).
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1641statin assignment in which clinical judgment and
informed patient preference could be used to
individualize the risk decision. As seen in Figure 1,
this discussion should include a review of other
risk factors, adherence to optimal lifestyle, the po-
tential for beneﬁt from a statin, the potential for
adverse effects/drug–drug interactions, and patient
preference.Furthermore, the risk assessment guideline rec-
ommended additional factors that could inform this
decision when it was uncertain. These were as fol-
lows: family history of premature ASCVD; coronary
artery calcium score $300 or $75th age-, sex-, and
race-adjusted percentiles; high sensitivity C-reactive
protein levels $2.0 mg/l; and an ankle-brachial index
<0.9. All these factors increase net reclassiﬁcation
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1642and are especially useful in older subjects. The
guidelines panel added low-density lipoprotein
cholesterol $160 mg/dl and a high lifetime risk of
ASCVD to identify younger subjects with genetic
dyslipidemia or severe expressions of a single risk
factor who could beneﬁt from statin therapy.
Many of the current study’s authors had noted in
earlier research that statin prescriptions increase,
especially in older adults, if a ﬁxed 7.5% risk
threshold is used (7). However, they acknowledged
that this was an estimate owing to the recommended
risk discussion. The 2013 risk assessment guidelines
cautioned that risk assessment is a probabilistic
and imperfect exercise (6). However, a study using
computed tomography angiography conﬁrmed the
beneﬁt of the new guidelines in risk prediction (8).
When the computed tomography ﬁndings were
examined, the current guidelines assigned statins
to those with high atherosclerotic burden with
greater accuracy than the older guidelines that used
low-density lipoprotein cholesterol targets only.
Indeed, this study demonstrated that arbitrary targets
degrade the ability to assign statins to those who
beneﬁt most.
For most of the population, the pooled cohort
equations can be used to predict ASCVD risk well,
as noted in a representative U.S. community-based
sample (9). Although the pooled cohort equations
have strong representation from non-Hispanic white
and African-American subjects, there were insufﬁ-
cient data for other ethnicities (5). Thus, there are
groups in whom over- and underprediction occur.
Compared with non-Hispanic white subjects, the
estimated 10-year risk of ASCVD may be lower in
some Hispanic (e.g., Mexican-American) subjects
and some Asian-American (e.g., East Asian ancestry)
subjects and higher in American-Indian popula-
tions and Asian-American subjects of South Asianancestry (5,10). In addition, clinicians should con-
sider that low-risk, educated volunteers for clinical
trial cohorts, many of whom were health care
professionals, also exhibit overestimation by risk
assessment (11).
Factors that may result in underprediction include
presence of human immunodeﬁciency virus, solid
organ transplantation, and rheumatoid arthritis
and other inﬂammatory disorders. The guidelines
speciﬁcally target clinician–patient discussions for
these groups. Polypharmacy is common in these
patients, underscoring the importance of addressing
drug–drug interactions.
Thus, after a risk discussion, a 68-year-old subject
with optimal or near-optimal risk factors may decide
not to receive a statin, even if risk is >7.5%.
Conversely, a 45-year-old South-Asian individual
with a positive family history may elect statin treat-
ment with a risk score <7.5%.
In conclusion, the clinician–patient discussion of-
fers an opportunity in which these insights, as well as
those gleaned from the age- and sex-speciﬁc thresh-
olds espoused by Navar-Boggan et al. (1), can be
applied. The current guideline’s strategy for reducing
ASCVD risk in lower risk primary prevention begins
with an estimation of global ASCVD risk. This initi-
ates a risk discussion, leading to a decision that
considers RCT evidence, clinician knowledge of the
patient’s speciﬁc attributes, and informed patient
preference. Decision making does not rely exclu-
sively on ﬁxed thresholds but on coherent actions
that help achieve the ultimate strategic goal of
ASCVD risk reduction.
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